Annals of Oncology
Journal Abbreviation: ANN ONCOL
ISSN: 0923-7534
eISSN: 1569-8041
Publisher: Elsevier
Publications (160)
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019)
Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al.
Conference contribution
Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019)
Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al.
Conference contribution
A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019)
Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al.
Conference contribution
Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019)
Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al.
Conference contribution
Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population (2019)
Pavel ME, Broberg P, Caplin M, Ruszniewski P, Strosberg J, Santoro P, Ravasi L, Krenning E
Conference contribution
Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019)
Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al.
Conference contribution
Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019)
Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al.
Conference contribution
Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019)
Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al.
Conference contribution
Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019)
Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al.
Conference contribution
Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019)
Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al.
Conference contribution